Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $211.65 | Total: $1,058.25 |
| 1 | 10 | $179.28 | Total: $1,792.80 |
| 1 | 25 | $151.89 | Total: $3,797.25 |
| 1 | 50 | $129.48 | Total: $6,474.00 |
| 1 | 100 | $112.05 | Total: $11,205.00 |
Overview
Zindoxifene (D 16726) is an anti-estrogenic compound with antitumor activity that can be used in studies of breast and prostate cancer.
Chemical Properties
| Molecular Formula | C21H21NO4 |
| Molecular Weight | 351.4 |
| CAS Numbers | 86111-26-4 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C(OC=1C=CC(=CC1)C2=C(C3=CC(OC(=O)C)=CC=C3N2CC)C)C |
Storage and Handling
0C Short Term, -20C Long Term
References
Stein RC, et al. Phase III study of the anti-oestrogen zindoxifene [D16726] in the treatment of advanced breast cancer. A Cancer Research Campaign Phase III Clinical Trials Committee study. Br J Cancer. 1990 Mar;61[3] 451-3.